A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were not given the opportunity to know whether they carried APOE4, a genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback